Cardiovascular DiscoveryConsider us your satellite cardiovascular lab and think tank. Investigating heart failure, pulmonary arterial hypertension, atrial fibrillation, thrombosis and ischemia reperfusion are our specialties.
CorDynamics is the only CRO providing clients with tailored study designs, collaborative model development and industry know-how to aid in all stages of drug discovery.
Our drug discovery services offer a streamlined process with an eye on industry compliance and customizable design to replicate nearly any experimental scenario. Our experienced researchers understand the need for quick turnaround time, solid data and expert interpretation to address the pressing cardiovascular questions surrounding lead optimization.
- Heart Failure
- Pulmonary Arterial Hypertension
- Atrial Fibrillation
CorDynamics is the only CRO dedicated to answering your cardiovascular toxicology and safety pharmacology questions for your lead compound today—rather than reacting tomorrow.
Investigating cardiac toxicity—the industry's most pressing issue—is our specialty. From lead optimization in drug discovery to GLP, CorDynamics offers comprehensive cardiovascular toxicology and safety pharmacology studies.
Our proven techniques, unparalleled timelines and customized approaches are designed to fit seamlessly into your preclinical drug development workflow. Our cardiovascular researchers work in conjunction with your project teams interpreting previous data, collaborating on de-risking strategies and executing regulatory-compliant examinations.
Our cardiovascular studies leverage the isolated Langendorff heart, anesthetized models and conscious telemetry subjects to investigate:
- Prolonged QT Interval
- Heart Rate
- Blood Pressure
- Cardiac Function
Telemetry models are the physiological ‘gold-standard’ used to interrogate the cardiovascular effects of compounds.
Telemetry studies are designed to client specifications and range from comprehensive GLP examinations of test article on hemodynamic and electrocardiograms to the screening of lead compounds early in preclinical drug development. Multiple endpoints are available for data collection and analysis, ensuring specified data needs are met.
Screening modes leverage a physiologically relevant paradigm with rapid scheduling and quick turnaround to enable key decision-making. In addition to evaluating electrocardiographic parameters, the systemic hemodynamic effects of a compound are simultaneously observed in the conscious, unrestrained subject.
- ECG and hemodynamics
- Left ventricular pressure
- Dual Pressure (systemic circulation + left ventricular/pulmonary arterial pressures)
- Respiratory telemetry (respiratory parameters + blood pressure + ECG)
- Electrophysiological testing
- High fidelity quasi beat-to-beat QT interval correction
- Sling-restrained and free-roaming
- Video monitoring capabilities